COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects with Hematological Malignancies

Protocol No
KANGPU-KPG-818-HEM-101
Principal Investigator
Nirav Shah
Phase
I
Summary
The purpose of this study is to find out about the safety and tolerability of the study drug, KPG-818 for the treatment of hematological malignancies. This study will also help to identify a recommended dose to study further in subjects with these selected hematological malignancies.
Description
Open-label, multiple-ascending dose study to evaluate the safety, PK, and preliminary clinical activity of KPG-818 as a single agent in adult subjects with selected hematological malignancies, except for multiple myeloma indication. KPG-818 will be used in combination with dexamethasone for dose escalation and dose expansion. The study will consist of 2 parts: Part 1 dose escalation and Part 2 dose expansion.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL